文献速递生殖医学

双调蛋白对多囊卵巢综合征患者卵母细胞成熟及其分子驱动因素的积极作用

Positive effects of amphiregulin on human oocyte maturation and its molecular drivers in patients with polycystic ovary syndrome.
PubMed 文献 · Hum Reprod · 2021-01-01

这项前瞻性随机队列研究纳入30名多囊卵巢综合征(PCOS)患者,比较含双调蛋白(100 ng/ml)与不含双调蛋白的培养液对卵母细胞体外成熟(IVM)的影响。结果显示双调蛋白组卵母细胞成熟率显著提高(67.6% vs 55.2%,RR 1.22,95%CI 1.08-1.38,P=0.001),但临床妊娠、持续妊娠和活产率组间无显著差异。

要点

  • 双调蛋白组卵母细胞成熟率显著高于对照组(67.6% vs 55.2%,RR 1.22,95%CI 1.08-1.38)。
  • 双调蛋白组每患者MII卵母数中位数显著高于对照组(7.0 vs 6.0,P=0.01)。
  • 临床妊娠、持续妊娠和活产率组间无显著差异。

核心结论

  • 在PCOS患者IVM中,成熟培养液中添加双调蛋白100 ng/ml可显著提高卵母细胞成熟率。
  • 但临床妊娠、持续妊娠和活产率组间无显著差异。

研究设计与样本

  • 前瞻性随机队列研究,在越南一家学术性不孕中心进行,2019年4月至12月。
  • 纳入30名PCOS患者,共671个同胞卵母细胞等量分配至含双调蛋白组(CAPA-AREG)或不含双调蛋白组(CAPA-Control)。
  • 第一阶段:卵母细胞在含或不含双调蛋白100 ng/ml的培养液中成熟,受精后第3天优质胚胎玻璃化冷冻。
  • 第二阶段:患者随机接受CAPA-AREG或CAPA-Control胚胎移植;若无随机组胚胎,则移植另一组胚胎。

主要发现

  • 每患者分析中,CAPA-AREG组MII卵母细胞数中位数(四分位距)显著高于CAPA-Control组(7.0[5.3,8.0] vs 6.0[4.0,7.0],P=0.01)。
  • 按卵母细胞分析,CAPA-AREG组成熟率显著高于CAPA-Control组(67.6% vs 55.2%;RR 1.22,95%CI 1.08-1.38;P=0.001)。
  • 临床妊娠率(66.7% vs 42.9%;RR 1.56,95%CI 0.77-3.14)、持续妊娠率(53.3% vs 28.6%;RR 1.87,95%CI 0.72-4.85)和活产率(46.7% vs 28.6%;RR 1.63,95%CI 0.61-4.39)在CAPA-AREG组数值较高,但均无显著差异。
  • CAPA-AREG组卵丘细胞中类固醇生成、排卵级联、氧化还原和葡萄糖代谢及转录相关基因表达发生显著改变。
  • 卵丘细胞中TRPM7、VCAN和JUN三个基因表达与胚胎质量显著相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究仅纳入越南PCOS女性,限制普适性。
  • 样本量小,发现应视为探索性。
  • 需要更大患者队列确认双调蛋白的积极效应是否转化为IVM患者生育结局的改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does use of medium containing amphiregulin improve meiotic maturation efficiency in oocytes of women with polycystic ovary syndrome (PCOS) undergoing in vitro maturation (IVM) preceded by a capacitation culture step capacitation IVM (CAPA-IVM)? SUMMARY ANSWER: Use of medium containing amphiregulin significantly increased the maturation rate from oocytes retrieved from follicles with diameters <6 or ≥6 mm pre-cultured in capacitation medium. WHAT IS KNOWN ALREADY: Amphiregulin concentration in follicular fluid is correlated with human oocyte developmental competence. Amphiregulin added to the meiotic trigger has been shown to improve outcomes of IVM in a range of mammalian species. STUDY DESIGN, SIZE, DURATION: This prospective, randomized cohort study included 30 patients and was conducted at an academic infertility centre in Vietnam from April to December 2019. Patients with PCOS were included. PARTICIPANTS/MATERIALS, SETTING, METHODS: In the first stage, sibling oocytes from each patient (671 in total) were allocated in equal numbers to maturation in medium with (CAPA-AREG) or without (CAPA-Control) amphiregulin 100 ng/ml. After a maturation check and fertilization using intracytoplasmic sperm injection (ICSI), all good quality Day 3 embryos were vitrified. Cumulus cells (CCs) from both groups were collected at the moment of ICSI denudation and underwent a molecular analysis to quantify key transcripts of oocyte maturation and to relate these to early embryo development. On return for frozen embryo transfer (second stage), patients were randomized to have either CAPA-AREG or CAPA-Control embryo(s) implanted. Where no embryo(s) from the randomized group were available, embryo(s) from the other group were transferred. The primary endpoint of the study was meiotic maturation efficiency (proportion of metaphase II [MII] oocytes; maturation rate). MAIN RESULTS AND THE ROLE OF CHANCE: In the per-patient analysis, the number of MII oocytes was significantly higher in the CAPA-AREG group versus the CAPA-Control group (median [interquartile range] 7.0 [5.3, 8.0] versus 6.0 [4.0, 7.0]; P = 0.01). When each oocyte was evaluated, the maturation rate was also significantly higher in the CAPA-AREG group versus the CAPA-Control group (67.6% versus 55.2%; relative risk [RR] 1.22 [95% confidence interval (CI) 1.08-1.38]; P = 0.001). No other IVM or embryology outcomes differed significantly between the two groups. Rates of clinical pregnancy (66.7% versus 42.9%; RR 1.56 [95% CI 0.77-3.14]), ongoing pregnancy (53.3% versus 28.6%; RR 1.87 [95% CI 0.72-4.85]) and live birth (46.7% versus 28.6%; RR 1.63 [95% CI 0.61-4.39]) were numerically higher in the patients who had CAPA-AREG versus CAPA-Control embryos implanted, but each fertility and obstetric outcome did not differ significantly between the groups. In the CAPA-AREG group, there were significant shifts in CC expression of genes involved in steroidogenesis (STAR, 3BHSD), the ovulatory cascade (DUSP16, EGFR, HAS2, PTGR2, PTGS2, RPS6KA2), redox and glucose metabolism (CAT, GPX1, SOD2, SLC2A1, LDHA) and transcription (NRF2). The expression of three genes (TRPM7, VCAN and JUN) in CCs showed a significant correlation with embryo quality. LIMITATIONS, REASONS FOR CAUTION: This study included only Vietnamese women with PCOS, limiting the generalizability. Although 100 ng/ml amphiregulin addition to the maturation culture step significantly improved the MII rate, the sample size in this study was small, meaning that these findings should be considered as exploratory. Therefore, a larger patient cohort is needed to confirm whether the positive effects of amphiregulin translate into improved fertility outcomes in patients undergoing IVM. WIDER IMPLICATIONS OF THE FINDINGS: Data from this study confirm the beneficial effects of amphiregulin during IVM with respect to the trigger of oocyte maturation. The gene expression findings in cumulus indicate that multiple pathways might contribute to these beneficial effects and confirm the key role of the epidermal growth factor system in the stepwise acquisition of human oocyte competence. STUDY FUNDING/COMPETING INTEREST(S): This work was funded by the Vietnam National Foundation for Science and Technology Development (NAFOSTED; grant number FWO.106-YS.2017.02) and by the Fund for Research Flanders (FWO; grant number G.OD97.18N). L.N.V. has received speaker and conference fees from Merck, grants, speaker and conference fees from Merck Sharpe and Dohme, and speaker, conference and scientific board fees from Ferring. T.M.H. has received speaker fees from Merck, Merck Sharp and Dohme and Ferring. J.S. reports speaker fees from Ferring Pharmaceuticals and Biomérieux Diagnostics and grants from FWO Flanders, is co-inventor on granted patents on CAPA-IVM methodologies in USA (US10392601B2), Europe (EP3234112B1) and Japan (JP 6806683 registered 08-12-2020) and is a co-shareholder of Lavima Fertility Inc., a spin-off company of the Vrije Universiteit Brussel (VUB, Brussels, Belgium). NA, TDP, AHL, MNHN, SR, FS, EA and UDTH report no financial relationships with any organizations that might have an interest in the submitted work in the previous three years, and no other relationships or activities that could appear to have influenced the submitted work. TRIAL REGISTRATION NUMBER: NCT03915054.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Akin N, Le AH, Ha UDT, et al. Positive effects of amphiregulin on human oocyte maturation and its molecular drivers in patients with polycystic ovary syndrome. Hum Reprod. 2021. PMID: 34741172. doi:10.1093/humrep/deab237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。